Senotherapeutic Peptide reduces biological skin age and improves skin health indicators
Hello everyone. It was published today a paper that described the research which led to the identification of and testing of the peptide, that reduces senescent skin cells. This peptide has been used in the world’s first (as far I know) product that is on the market, that reduces senescent skin cells in humans. You can find the paper in I don’t believe it’s normal that a product is sold that reduces senescent cell count. The public has finally heard about this after years of watching Aubrey de Grey speak and reading about promising senescent cell research and the formation of companies that are researching how to reduce senescent cell numbers. This paper is important because it will allow the rejuvenation industry to analyze it and prepare to take advantage of this opportunity. OneSkin is the company that organized the research and launched this product. Its CEO, Carolina Reis has presented their research at several rejuvenation conferences over the past months. OneSkin has its own interests, but is also a leader in the rejuvenation industry, paving the way for other companies.
The aging of the skin has been associated with aesthetics and beauty. Interventions have therefore focused on improving skin appearance but not necessarily health, function and resilience. Recent studies have shown that cellular senescence plays a significant role in the age-related decline of skin function and can influence organismal health, and potentially, lifespan. In this study, a 2-step screening was conducted to identify peptides that could reduce cellular senescence of human dermal fibroblasts from Hutchinson-Gilford Progeria patients. We built a 764 peptide library by scanning amino acids using the four top peptides from the first screening round. The second screen identified peptide 14 among the 764 peptides. Peptide 14 reduced HDF senescence induced through HGPS (chronological aging), ultraviolet-B radiation and etoposide treatments, but without causing significant cell death. This was likely due to modulating pathways for longevity and senescence. The effectiveness of peptide 14, as measured by the Skin-SpecificDNA methylation clock MolClock, was further validated using human skin samples and biopsies. Peptide 14 improved skin health, reduced senescent cells markers and also the biological age. Topical application peptide 14, the gold standard in anti-aging skincare, outperformed Retinol. In two independent tests, we found that peptide 14, when applied over a long period of time, significantly increased the healthspan and lifespan of C.elegans worms. The potential of geroprotective uses for the senotherapeutic substances identified by our screening platform goes beyond the skin.
SAV, MR, and AZ are cofounders of NemaLife Inc., a startup company that commercializes microfluidics devices licensed from Texas Tech University. SAV, MR and TA receive royalties for being named inventors of a Texas Tech University patent.
Source:
https://www.biorxiv.org/content/10.1101/2020.10.30.362822v2
